Company intelligence / Profile preview

Morphic Medical

Lexington/Boston area, Massachusetts, United Statesmorphicmedical.com ↗

Ownership: Private
Employees: ~15
Development stage: Commercial

Overview

The company's lead product, formerly known as EndoBarrier and now rebranded as RESET, is an endoscopically delivered device designed to treat type 2 diabetes and obesity by mimicking some effects of gastric bypass surgery without invasive procedures. Clinical trials have shown efficacy in improving glycemic control and promoting weight loss. The device is not yet approved for sale in the United States but has been used under investigational protocols and is available in select international markets.

Therapeutic areas: Endocrinology
Modalities: Device
Industry: Implantable Medical Devices

Drug pipeline

2 assets

RESET

Commercial

Indications: Type 2 diabetes, Obesity

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Morphic Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Morphic Medical.

Explore the full profile